Synthetic peptide studied as a triple agonist at the GLP-1, GIP, and glucagon receptors in metabolic research models.
Wholesale or institutional quantities? Request a custom quote — we'll follow up to discuss.
Every batch is independently tested before it's listed — no exceptions.
Retatrutide is a single synthetic peptide engineered to activate three separate metabolic receptors at once — GIP, GLP-1, and glucagon — making it the first "triple agonist" to reach late-stage clinical trials. Adding glucagon-receptor activity on top of the GLP-1/GIP combination already used by drugs like tirzepatide is significant because glucagon signaling independently increases energy expenditure and hepatic fat oxidation, effects the other two receptors don't produce alone. In a 48-week Phase 2 obesity trial published in the New England Journal of Medicine, the highest studied dose produced mean weight loss of 24.2%, versus 2.1% on placebo — among the largest effects reported for an incretin-based therapy to date.
Purity results across recent lots — consistency you can check.
No reviews yet. Verified buyers can leave a review from their account once an order is completed.